Inappropriate antidiuretic hormone secretion after high-dose thiotepa

Bone Marrow Transplant. 1999 Sep;24(5):571-2. doi: 10.1038/sj.bmt.1701922.

Abstract

High-dose thiotepa has been successfully included in a variety of conditioning regimens for stem cell transplantation in hematological and solid neoplasms. Toxicity of high-dose thiotepa mainly manifests as profound myeloablation and some degree of liver damage. We report a case of inappropriate secretion of antidiuretic hormone (SIADH) in a patient with primary CNS lymphoma who underwent therapy with high-dose thiotepa.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / therapy
  • Combined Modality Therapy
  • Cranial Irradiation
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Inappropriate ADH Syndrome / chemically induced*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / radiotherapy
  • Lymphoma, Non-Hodgkin / therapy
  • Thiotepa / administration & dosage
  • Thiotepa / adverse effects*
  • Transplantation Conditioning / adverse effects*

Substances

  • Thiotepa